Mary Christina Thomson - Jan 26, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
General Counsel & Secretary
Signature
/s/ Mary Christina Thomson
Stock symbol
SRRA
Transactions as of
Jan 26, 2022
Transactions value $
-$31,920
Form type
4
Date filed
1/28/2022, 03:47 PM
Previous filing
Jun 28, 2021
Next filing
Feb 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Options Exercise $26.1K +2K $13.04 2K Jan 26, 2022 Direct
transaction SRRA Common Stock Sale -$58K -2K -100% $29.00 0 Jan 26, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right to Buy) Options Exercise $0 +2K $0.00* 0 Jan 26, 2022 Common Stock 2K $13.04 Direct F2
transaction SRRA Stock Option (Right to Buy) Award $0 +12.3K $0.00 12.3K Jan 28, 2022 Common Stock 12.3K $12.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 21, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
F2 On July 28, 2021, the option vested as to 25% of the total shares granted on July 28, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on July 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares.